Connect with us

Replica Analytics’ new estimator uses synthetic data for more reliable evaluation of re-identification risk in datasets

Published

2 years ago

on

OTTAWA, ON, July 19, 2022 /PRNewswire/ – Replica Analytics, an Aetion company, has unveiled a novel approach to use synthetic data for a more accurate assessment of re-identification risks in datasets, to better manage privacy risks and enable greater data sharing in healthcare and other sectors.

“Re-identification risk is the probability that an adversary will correctly match a record in a dataset with a real person and until now, there has been no sufficiently reliable measure of this risk,” said Dr. Khaled El Emam, Senior Vice-President and General Manager of Replica Analytics, the premier science-based synthetic data generation technology provider to the healthcare industry. “Access to data and sharing de-identified datasets remain a challenge, in part due to privacy concerns. The re-identification risk estimator we have developed should help data custodians overcome those challenges.”

Most existing estimators provide a proxy for risk based on strong assumptions, as they cannot calculate the risk on a population because real population data is rarely available. Replica’s estimator leverages data synthesis technology to simulate the unavailable population dataset, so that re-identification risks can be calculated much more accurately. Synthetic data generation (SDG) involves training a machine learning model to master the statistical patterns and properties of a real dataset. The trained model, when implemented properly, is then used to create a synthetic dataset which maintains the traits of the original dataset, but with no one-to-one mapping back to a person, so the synthetic data mitigates privacy risks.

Measuring re-identification risk using a synthetic estimator to enable data sharing, a study recently published by the journal, PLOS ONE, includes a detailed analysis of the concepts behind Replica’s new risk estimator, an evaluation of its performance and relevant case studies. The results show that the estimator reliably outperforms other approaches, across different dataset sizes and varying complexity, achieving a high degree of accuracy, and offering a consistent estimate of the probability of re-identification risk. The study was also the focus of a webinar and blog post.

The new approach is another example of the usefulness and effectiveness of SDG technology in assessing and mitigating privacy risks and enabling data sharing. Replica’s estimator can now be used through the Replica Synthesis software to better assess re-identification risks in real datasets. If the risk is deemed too high, organizations can choose to synthesize the data and then use the company’s privacy assurance functionality to measure any risk in the synthetic data to demonstrate that it is much lower than the real data.

About Replica Analytics, an Aetion company

Replica Analytics is the premier science-based SDG technology provider to the healthcare industry. The company is a pioneer in the development of unique technologies for generating privacy-protective synthetic data that maintain the statistical properties of real-world data (RWD). The company was acquired in late 2021 by Aetion, the leading regulatory-grade real-world evidence (RWE) technology provider. Replica Synthesis software provides a full suite of synthetic data generation and evaluation capabilities that can solve multiple grand challenges facing the life sciences industry, and health research in general. For more information, visit: https://replica-analytics.com/.

About Aetion

Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us at @aetioninc.

View original content:https://www.prnewswire.com/news-releases/replica-analytics-new-estimator-uses-synthetic-data-for-more-reliable-evaluation-of-re-identification-risk-in-datasets-301589358.html

SOURCE Replica Analytics

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Immorta Bio to Present New Data on SenoVax™ and StemCell Revivify™ at Biotech Showcase 2025

Published

10 minutes ago

on

January 10, 2025

By

Senolytic Immunotherapy and Cellular Rejuvenation platforms are progressing toward clinical development

MIAMI, Jan. 10, 2025 /PRNewswire/ — Immorta Bio Inc., a leader in longevity-focused biotechnologies, announced today that it will present its latest developments at the upcoming Biotech Showcase in San Francisco, CA. The company’s presentation will provide insights into its groundbreaking research and technological advancements aimed at Treating Diseases of Aging and Treating Aging as Disease™.

Details of the presentation are as follows:

Event: Biotech Showcase 2025
Date: January 14, 2025
Time: 4 PM Pacific
Location: Franciscan C, Ballroom Level

Immorta Bio’s innovative platform SenoVax™, a dendritic cell-based vaccine designed to target and eliminate senescent cells. Preclinical studies have demonstrated its potential to transform the tumor microenvironment by clearing these cells, which are associated with aging and disease progression. Furthermore, in animal models of multiple solid tumor cancers (lung, breast, glioma, pancreatic), SenoVax™ induced significant tumor regression by enhancing immune responses, underscoring its promise as a therapeutic solution for both cancer treatment and longevity research.

The company’s StemCell Revivify™, a set of personalized young and immortal progenitor and mesenchymal stem cells have shown an ability to achieve dramatic recovery of failing organs in multiple animal models. Proprietary iPSC-based stem cell therapies have been developed to provide scalable, practical, and economical solutions.

“We are thrilled to showcase our recent progress and share our vision for tackling the diseases of aging as well as the aging itself,” said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio. “At Immorta Bio, we believe that combining cutting-edge science with a deep understanding of the biology of aging can transform how we address major medical challenges. The Biotech Showcase offers an invaluable platform to engage with innovators, collaborators, and investors while we highlight how our breakthroughs in longevity science are paving the way for healthier, longer lives.”

To learn more about the event, please visit https://informaconnect.com/biotech-showcase/. To schedule a one-on-one with Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, during the event, please email kbash@immortabio.com

About Immorta Bio
Immorta Bio Inc. is a scientific longevity company developing personalized cellular therapeutics focused on Treating Diseases of Aging and Treating Aging as a Disease™. We are advancing longevity medicine by harnessing patient-derived rejuvenated stem cells and enhanced immune cells, restoring the body’s natural ability to combat cancers and age-related diseases. Our mission is to address the root causes of aging and bring resilience and vitality back to you.

To learn more about Immorta Bio’s research initiatives, visit immortabio.com, LinkedIn and X.

Media Contact

David Schull  
Russo Partners
858-717-2310
388575@email4pr.com

Kate Bash
Chief Commercial Officer
Immorta Bio
388575@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/immorta-bio-to-present-new-data-on-senovax-and-stemcell-revivify-at-biotech-showcase-2025-302347953.html

SOURCE Immorta Bio Inc.

Continue Reading

Technology

Breaking Stereotypes: New 3Fun Survey Reveals Media’s Missteps in Polyamory Representation

Published

10 minutes ago

on

January 10, 2025

By

NEW YORK, Jan. 10, 2025 /PRNewswire/ — Despite growing visibility, only 11% of polyamorous individuals feel media portrayals align with their real-life experiences, according to a new survey by 3Fun, the leading dating app for open-minded singles and partners seeking like-minded connections. The survey, conducted among 1,312 3Fun users, highlights how media misrepresentation shapes public perceptions, reinforces stereotypes, and impacts user expectations on dating platforms like 3Fun.

Key Findings from the 3Fun Survey:

Limited Representation: Nearly 40% of respondents said they rarely see polyamorous relationships in mainstream media, while 17% reported never seeing them at all.Social Media Influence: Platforms like Instagram and TikTok are driving perceptions of polyamory for 40% of users, far surpassing traditional media like TV and film (10%).Accuracy Issues: Only 11% of respondents described media portrayals as “very accurate,” while 52% rated them as “rarely accurate” or “completely inaccurate.”Mixed Progress: While 39% believe portrayals have improved, 38% said they’ve noticed no change at all.Normalization vs. Stereotypes: Social media is a double-edged sword—40% think it normalizes polyamory, but 34% believe it reinforces harmful stereotypes.Global vs. Local Media: Over 21% noted global media tends to be more open-minded about polyamory than local outlets, which are often conservative or avoid the topic altogether.

“The data from this survey shows how far we still have to go in achieving authentic representation of polyamory in media and pop culture,” said Max Ma, Founder and CEO of 3Fun. “These portrayals don’t just shape public opinion—they directly influence how our users feel about their relationships and their ability to live openly. At 3Fun, we’re dedicated to creating a supportive community where everyone can explore their desires without fear of judgment.”

The Real Impact of Misrepresentation

Nearly half of respondents (47%) identified cultural and societal norms as the biggest barriers to societal acceptance of polyamory—more significant than concerns about media portrayal or visibility. However, respondents emphasized that better representation would lead to:

Easier conversations about polyamory (32%)Improved understanding within their social circles (21%)

Gigi Engle, certified sex and relationship psychotherapist and 3Fun’s resident intimacy expert, echoed this sentiment: “Representation matters. Media has the power to normalize relationships and dismantle stereotypes, but only when done thoughtfully. This survey shows a clear need for creators to approach polyamory with authenticity and care.”

Creating a World Where Love Knows No Limits

The findings highlight the role platforms like 3Fun play in bridging the gap between perception and reality. With over 10 million downloads and 3 million verified active users worldwide, 3Fun provides a safe, inclusive space for polyamorous individuals and couples to connect, explore, and thrive.

Join us in building a community where love is celebrated in all its forms. Download 3Fun today and discover a world where love knows no limits.

For more information, visit www.go3fun.co.

About 3Fun:

3Fun, with over 10 million downloads and 3 million verified active users worldwide, is the leading dating app for open-minded singles and partners to meet like-minded people. The platform provides a safe and inclusive space for users to explore ethical open relationships and polyamory lifestyles, fostering community and connection without judgment. Learn more at www.go3fun.co.

Media Contact:
Britni Ackrivo
backrivo@gregoryfca.com
484-504-9920

View original content:https://www.prnewswire.com/news-releases/breaking-stereotypes-new-3fun-survey-reveals-medias-missteps-in-polyamory-representation-302347759.html

SOURCE 3Fun

Continue Reading

Technology

Powerfleet to Present at the 27th Annual Needham Growth Conference

Published

10 minutes ago

on

January 10, 2025

By

WOODCLIFF LAKE, N.J., Jan. 10, 2025 /PRNewswire/ — Powerfleet, Inc. (Nasdaq: AIOT) today announced that management is scheduled to present at the 27th Annual Needham Growth Conference on Tuesday, January 14th at 4:30pmET and meet with investors to discuss how Powerfleet is enacting meaningful business change through effective data insights for its customers and underpinning their digital transformations.  

The link to the live webcast of the Company’s presentation will be available by visiting Powerfleets website at https://ir.powerfleet.com/events-presentations/events.

ABOUT POWERFLEET
Powerfleet (Nasdaq: AIOT; JSE: PWR) is a global leader in the artificial intelligence of things (AIoT) software-as-a-service (SaaS) mobile asset industry. With more than 30 years of experience, Powerfleet unifies business operations through the ingestion, harmonization, and integration of data, irrespective of source, and delivers actionable insights to help companies save lives, time, and money. Powerfleet’s ethos transcends our data ecosystem and commitment to innovation; our people-centric approach empowers our customers to realize impactful and sustained business improvement. The company is headquartered in New Jersey, United States, with offices around the globe. Explore more at www.powerfleet.com. Powerfleet has a primary listing on The Nasdaq Global Market and a secondary listing on the Main Board of the Johannesburg Stock Exchange (JSE).

Powerfleet Investor Contacts
Carolyn Capaccio and Jody Burfening
Alliance Advisors IR
AIOTIRTeam@allianceadvisors.com

Powerfleet Media Contact
Jonathan Bates
jonathan.bates@powerfleet.com
+44 7921 242 892

View original content to download multimedia:https://www.prnewswire.com/news-releases/powerfleet-to-present-at-the-27th-annual-needham-growth-conference-302347520.html

SOURCE Powerfleet

Continue Reading

Trending